Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00730691 · ClinicalTrials.gov registry record · Phase 3
Efficacy of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder
A Phase 3 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 781
- Enrollment target
NCT00730691 is a Phase 3 study that has completed, run by Takeda. The registered enrollment target is 781 participants.
The verdict
NCT00730691, a Phase 3 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 781 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and efficacy of vortioxetine, once daily (QD), in adults with generalized anxiety disorder.
Interventions
- DRUG Placebo
- DRUG Duloxetine
- DRUG Vortioxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 781 participants |
| Start Date | 2008-06 |
| Est. Completion | 2009-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00730691
The ClinicalTrials.gov registry entry for NCT00730691 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 781 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00730691 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00730691 about?
NCT00730691 is a clinical study titled "Efficacy of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder". The purpose of this study is to determine the safety and efficacy of vortioxetine, once daily (QD), in adults with generalized anxiety disorder.
What is the current status of trial NCT00730691?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 781 participants. The study started on 2008-06. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00730691?
The interventions under investigation include: Placebo (DRUG), Duloxetine (DRUG), Vortioxetine (DRUG).
Who is sponsoring clinical trial NCT00730691?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.